To hear about similar clinical trials, please enter your email below
Trial Title:
Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection
NCT ID:
NCT06541327
Condition:
Lymphoma, Non-Hodgkin
Conditions: Official terms:
Lymphoma
Lymphoma, Non-Hodgkin
Conditions: Keywords:
CAR-T
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Other
Intervention:
Intervention type:
Drug
Intervention name:
Chimeric Antigen Receptor
Description:
CAR-T
Arm group label:
CAR-T
Other name:
Chimeric antigen receptor modified T cells
Summary:
This study aims to collect clinical data from adult patients with relapsed or refractory
non-Hodgkin's lymphoma (r/r NHL) receiving cellular immunotherapy to establish a large
database of cellular immunotherapy for Chinese patients.
Detailed description:
This study aims to collect efficacy and safety data from adult patients with r/r NHL who
received cellular immunotherapy between January 2017 and December 2040. Study
investigators will determine the most appropriate diagnostic and treatment plans for
patients based on clinical practice, without any intervention due to the existence of
this study. No grouping will be conducted, and subgroup analyses will be performed based
on the collected data.
Data collection process:
Clinical data will be collected from patients before cellular immunotherapy, before
immune cell infusion, on the day of infusion, and at the last visit or follow-up within
24 months post-infusion. This includes collecting efficacy data, adverse events related
to cellular immunotherapy, and survival data. Additionally, any new tumors, pathological
findings, and other relevant laboratory or auxiliary examination data will be collected.
Criteria for eligibility:
Study pop:
Adult patients with relapsed or refractory lymphoma receiving cellular immunotherapy
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Adult patients with a confirmed diagnosis of r/r B-NHL (including r/r DLBCL, r/r FL,
r/r MCL, HGBL-NOS, FL3b, r/r MZL, transformed lymphomas such as MCL) and r/r T-cell
lymphoma, who have received informed consent waivers;
- Patients who have received or are receiving cellular immunotherapy, with cellular
immunotherapy products including the following categories: cytokine-induced killer
cell therapy (CIK), tumor-infiltrating lymphocytes (TIL), cytokine-induced killer
cell-dendritic cell mixed therapy (DC-CIK), chimeric antigen receptor T cells, NK
cells or macrophage therapy (CAR-T, CAR-NK, CAR-M), T-cell receptor chimeric T cell
therapy (TCR-T), dendritic cell therapy.
Exclusion Criteria:
- NA
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Locations:
Facility:
Name:
Department of Hematology, Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Address:
City:
Shanghai
Country:
China
Status:
Recruiting
Contact:
Last name:
Zixun Yan
Email:
yzx12119@rjh.com.cn
Start date:
May 15, 2024
Completion date:
December 31, 2040
Lead sponsor:
Agency:
Ruijin Hospital
Agency class:
Other
Source:
Ruijin Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06541327
